Hong Kong – U.S. Based Insilico Medicine headed Alex Zhavoronkov, founder and CEO uses neural networks in a machine learning model that crunches reams of biological, chemical and clinical trial data. The company uses a platform called PandaOmics to discover new drug targets; another AI platform called Chemistry42 to design small molecule drugs against a target; and a final platform called InClinico to predict the results of a clinical trial to improve the design of the trial.
The company’s lead candidate INS018_055 blocks an AI-discovered drug target to treat Idiopathic Pulmonary Fibrosis. The condition involves scarring in the lungs that leads to a drop in lung function, and eventually death. INS018_055 having completed a Phase I Clinical Trial is expected to enter a Phase 2A Trial early in 2023.